Results 81 to 90 of about 209,106 (262)

Low SLC8A1 in Colorectal Cancer Dictates Radiotherapy Resistance Through Calcium‐Dependent ANXA2+sEVs Driving M2 Polarization of TAMs

Advanced Science, EarlyView.
SLC8A1 deficiency in colorectal cancer cells increases intracellular calcium signaling, promoting the secretion of ANXA2‐enriched small extracellular vesicles. These vesicles reprogram tumor‐associated macrophages towards an M2 phenotype, which in turn fosters a tumor microenvironment conducive to radioresistance and is associated with poor patient ...
Yimin Fang, Jinghan Zhu, Qian Xiao, Qichun Wei, Xiujing He, Ping Li, Kai Jiang, Yue Liu, Yeting Hu, Weiwei Yu, Chuansheng Guo, Sheng Chen, Jian Zhao, Siqi Dai, Jingsun Wei, Hang Yang, Tongtong Bu, Kefeng Ding, Haiyan Chen   +18 more
wiley   +1 more source

Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab

OncoImmunology, 2018
A high concentration of circulating vascular endothelial growth factor (VEGF) in cancer patients is associated with an aggressive tumor phenotype. Here, serum levels of 27 cytokines and blood cell counts were assessed in breast cancer patients receiving ...
Shakila Jabeen, Manuela Zucknick, Marianne Nome, Ruth Dannenfelser, Thomas Fleischer, Surendra Kumar, Torben Lüders, Hedda von der Lippe Gythfeldt, Olga Troyanskaya, Jon Amund Kyte, Anne-Lise Børresen-Dale, Bjørn Naume, Xavier Tekpli, Olav Engebraaten, Vessela Kristensen   +14 more
doaj   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

Advanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng, Chaoying Wei, Zhitong Niu, Jinxin Chen, Guojie Long, Yingzhen Weng, Qiufeng Liu, Yue Jiang, Panpan Wang, Ronghua Zhang, Qiang Yu, Xiaojian Wu, Wenyu Wang   +12 more
wiley   +1 more source

Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment [PDF]

, 2013
Multimodal therapy concepts have been successfully implemented in the treatment of locally advanced gastrointestinal malignancies. The effects of neoadjuvant chemo- or radiochemotherapy such as scarry fibrosis or resorbtive changes and inflammation can ...
Rupert eLanger, Thies, Svenja, Svenja eThies, Rupert Langer, Langer, Rupert, Svenja Thies   +5 more
core   +2 more sources

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Breast Cancer: Targets and Therapy, 2022
Nusayba A Bagegni, Andrew A Davis, Katherine K Clifton, Foluso O Ademuyiwa Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USACorrespondence: Foluso O Ademuyiwa, Division of ...
Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO   +3 more
doaj  

Administered neoadjuvant and adjuvant therapy regimens.

, 2022
All regimens, both neoadjuvant and adjuvant therapy, with the number of cycles used for both patients treated with neoadjuvant therapy and upfront surgery. NAT = Neoadjuvant therapy, US = Upfront surgery. (DOCX)
Harri Mustonen (641410), Hanna Seppänen (751179), Jaana Hagström (476954), Anna Maria Nurmi (12524924), Caj Haglund (476956)   +4 more
core   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma

BackgroundNeoadjuvant immunotherapy for resectable stage III melanoma has demonstrated promising outcomes in recent trials, prompting a change in clinical practice in many countries.
van Akkooi, Alexander C. J., Int Neoadjuvant Melanoma Consortium INMC, Novis, Elan, Rautalin, Mervi, Amaria, Rodabe N.   +4 more
core   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source